The latest financial statement is for the quarter ending 2025-09-30.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Cash received in acquisition | 0 | - |
| Acquisition of property and equipment | 0 | - |
| Investment in securities | 0 | 0 |
| Net cash used in investing activities from continuing operations | 0 | 0 |
| Net cash provided by investing activities from discontinued operations | 0 | 0 |
| Net cash provided by investing activities | 0 | 0 |
| Net loss from continuing operations | -3,607,361 | -9,784,570 |
| Depreciation expense | 500 | 1,000 |
| Change in fair value of warrant liability | -59,203 | -722,108 |
| Loss on conversion of note payable | 43,200 | -96,646 |
| Loss on disposition of subsidiaries | 171,042 | -385,528 |
| Stock-based compensation | 1,820,433 | - |
| Common stock issued for services | 442,237 | 3,781,253 |
| Options expense | - | 162,874 |
| Amortization of debt discount | 1,755,349 | 994,640 |
| Amortization of right-of-use assets | 6,454 | 29,481 |
| Interest income | 0 | 62,500 |
| Accounts receivable, net | 590,050 | -11,106 |
| Prepaid expenses and deposits | -67,876 | 282,088 |
| Inventory | 234,521 | 0 |
| Other receivables | 0 | 80,469 |
| Lease liability | -6,465 | -30,514 |
| Accounts payable | 707,465 | -45,084 |
| Accrued liabilities | -772,068 | 486,362 |
| Current liabilities | -5,441 | 0 |
| Change in fair value of derivative liability | 2,356,428 | -59,594 |
| Net cash used in operating activities from continuing operations | -3,208,339 | -4,998,849 |
| Net cash provided by (used in) operating activities from discontinued operations | -5,346 | 8,145 |
| Net cash used in operating activities | -3,213,685 | -4,990,704 |
| Net cash used in financing activities from discontinued operations | 0 | 0 |
| Repayment of contingent liability | 0 | 0 |
| Proceeds from convertible note | 0 | - |
| Cash dividends paid | 0 | 0 |
| Proceeds from exercise of warrants | 0 | 0 |
| Proceeds from exercise of options | 0 | 0 |
| Proceeds from loan payable, related party | 16,000 | 100,000 |
| Deferred offering costs | - | 0 |
| Repayment of convertible notes | 3,333,333 | - |
| Gross proceeds from issuance of common stock | 6,871,319 | 4,597,999 |
| Net cash provided by (used in) financing activities from continuing operations | 3,553,986 | 4,697,999 |
| Net cash provided by (used in) financing activities | 3,553,986 | 4,697,999 |
| Net change in cash | 340,301 | -292,705 |
| Cash and cash equivalents at beginning of period | 308,096 | - |
| Cash and cash equivalents at end of period | 355,692 | - |
Scienture Holdings, Inc. (SCNX)
Scienture Holdings, Inc. (SCNX)